Due to its pivotal role on cognition processes and the fact that it is expressed not only in the brain but also in a wide variety of immune cells targeted during HIV infection, the α7-nAChR could emerge as a pharmacological intervention target to develop neuroprotective therapeutics for HIV-infected patients suffering from HAND. This evidence concerns the gene CHRNA7 and HIV-associated neurocognitive disorder.